US Stock MarketDetailed Quotes

BLRX BioLine Rx

Watchlist

0.470
+0.032+7.40%

Close Oct 16 16:00 ET

0.454
-0.016-3.36%

Post 20:01 ET

37.57MMarket Cap-1037P/E (TTM)

BioLine Rx Stock Forum

Trytosaveabit

16 hours ago

News

$BioLine Rx (BLRX.US)$ BioLineRx Announces USPTO Allowance Of New Composition Of Matter Patent Covering Composition Of Motixafortide

Keith Squires

Aug 30 10:17

$BioLine Rx (BLRX.US)$ only see this stock rising anywhere from $6-$13 to $21 from now to early next year.iam going to be right on this one so you all can buy me a new truck,hold moo mooers

Blue Coffee Brewing

Jul 31 09:57

Make the best use of the Features!

There are many features available and sometimes I use interpretation of indicator to have a quick decision filter to decide if should further look at the potential investment opportunity!

Q2 earnings challenge: Ride the market wave with moomoo

Trytosaveabit

May 30 06:13

Update

$BioLine Rx (BLRX.US)$ Benzinga· 1 min ago
BioLineRx Announces Multi-Center Phase 1 Trial Sponsored By St. Jude Children's Research Hospital To Evaluate Motixafortide For CD34+ Hematopoietic Stem Cell Mobilization For Gene Therapy Applications In Sickle Cell Disease

Trytosaveabit

May 6 06:07

Watching for data!

$BioLine Rx (BLRX.US)$ BioLineRx To Present Poster On Economic Model Data For APHEXDA Today At ISPOR 2024

Trytosaveabit

Apr 10 06:15

Update

$BioLine Rx (BLRX.US)$ BioLineRx Has Drawn-down The Second Tranche Of $20M Under Its Previously Announced $40M Non-Dilutive Debt Financing Agreement With Funds And Accounts Managed By Blackrock

Trytosaveabit

Mar 4 06:10

Update

$BioLine Rx (BLRX.US)$ BioLineRx Announces Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production, New Patent, When Issued, Will Be Valid Until December 2041

Stock Region

Mar 1 09:28

Renowned Investment Bank Reiterates Buy Rating For Israeli Medical Company

HC Wainwright & Co. Reiterates Buy on BioLine Rx, Maintains $21 Price Target: A Deep Dive into the Potential of $BLRX.
BioLine Rx (NASDAQ: $BLRX), an Israeli biopharmaceutical development company, recently received a reiterated buy rating from the renowned investment bank, HC Wainwright & Co. The financial institution has maintained a price target of $21 for BioLine Rx, indicating a positive outlook for the company's futur...